tbuckley/cabot-search huggingface dataset:
<i>The Philharmonic</i>
Authors: Robert M. Golub
Journal: JAMA (2011)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
419O Efficacy and safety of ceritinib in patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) and baseline brain metastases (BM) – results from ASCEND-2 and ASCEND-3
Authors: K. Park, D. Tan, M.-J. Ahn, C.-J. Yu, C.-M. Tsai, T. Hida, M. Nishio, F. Branle, C. Emeremni, T. Mok
Journal: Annals of Oncology (2015)
Pregnant women are too cautious about risk of medicines
Authors: Anne Gulland
Journal: BMJ (2016)

Pregnant women are overly cautious about the risks of over the counter and prescribed drugs, a study has found.1

The study of 1120 women found that many were unwilling to medicate common pregnancy symptoms such as nausea, urinary tract infections (UTIs), and aches and pains.

The women completed an online survey where they were asked which common conditions they had experienced during pregnancy. They were then asked about the extent to which …
AB0455 Good Response on Rituximab Treatment for Patients with Rheumatoid Arthritis Persists for Up to 4 Years
Authors: I.M. Visman, R. Agca, A. Voskuijl, W. Lems, M. Nurmohamed
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> With the advent of biological therapy a range of new drugs have come available for patients with rheumatoid arthritis (RA). Rituximab (RTX) is a lesser known, but effective treatment option for patients with RA. Obviously, data on long-term efficacy and safety in daily clinical practice is important as results obtained in short-term clinical registration trials might differ from those observed in long-term daily clinical practice. <h3>Objectives</h3> To ascertain the efficacy of long- term RTX treatment for RA <h3>Methods</h3> From February 2009 to February 2014, 97 consecutive patients were included in the rituximab for RA cohort at the Jan van Breemen research centre in Amsterdam, the Netherlands. <h3>Results</h3> The mean age was 58 years (SD:13), and 74 (76%) were female. At baseline, the median disease duration was 12 (5-18) years, and 75 (79%) were Rheumatoid factor positive. At baseline, 38 (41%) used methotrexate, 46 (49%) used prednisolone, and 18 (19%) a DMARD other than MTX. On average patients had used 3.4 (SD:1.6) DMARDs, 1.5 (1.1) biologicals. At 72, most (77%) patients had used at least one biological prior to start of rituximab. A total of 66 (68%) patients are currently on drug, and 31 (32%) patients have dropped out. The median follow-up duration was 1.1 (IQR:0.6-1.9) years for patients currently still on rituximab treatment, and 0.6 (0.1-1.1) years for drop-outs. The maximum follow-up duration was 3.8 years. The mean DAS-28 dropped significantly from 5.2 (SD: 1.4) at baseline to 4.3 (1.4) at 12 weeks. This improvement was sustained, and steadily improved further over the whole 3 years (see figure). The patient reported outcome of the health assessment questionnaire (HAQ) also showed a good initial response, however rose to baseline levels after 1.5 years before dropping again and much lower (see figure). <h3>Conclusions</h3> The initial good response on rituximab persists for at least 3 years of follow-up, with the decrease in DAS28 continuing for the entire 3 years. Over time, a satisfactory response both in HAQ and DAS28 was sustained. <h3>Disclosure of Interest</h3> None declared
Case 8-1976
Authors: Richard C. Cabot, Robert E. Scully, James J. Galdabini, Betty U. McNeely, Arthur A. Sasahara, Eugene J. Mark
Journal: New England Journal of Medicine (1976)

Presentation of CaseA 15-year-old girl was admitted to the hospital because of dyspnea.She was born of a normal pregnancy of a mother aged 41 years. Her early development was normal and comparable to that of her three older siblings. At the age of three years she entered another hospital because of bronchitis; for several years thereafter she had episodic respiratory-tract infections, with cough and wheezing, several times each winter. She had mumps and the usual exanthems in early childhood. Repeated examinations showed no murmur.She was otherwise well, with normal exercise tolerance, until 18 months before admission, when . . .
Rabies remains a ‘neglected disease’
Authors: A. R. Fooks
Journal: Eurosurveillance (2005)

Europe continually encounters the serious threat posed from zoonotic diseases including ancient bacterial agents such as Mycobacterium tuberculosis. The largest threat, however, is from RNA viruses such as the SARS-CoV, the Heninipah viruses, avian influenza viruses and emerging lyssaviruses.
Teaching residents the administrative aspects of psychiatric practice
Authors: J F Borus
Journal: American Journal of Psychiatry (1983)

As the trend toward the organization and bureaucratization of professional practice increases, psychiatrists will require a better understanding of the administrative aspects of their practice. However, a survey of the American Association of Directors of Psychiatric Residency Training indicated that less than one-third of residency programs currently require core training in this area. The author presents a curricular blueprint that specifies learning objectives and a series of graduated training experiences over the course of residency in which essential teaching about the administrative aspects of psychiatric practice can be provided.
Molecular status of non squamous non small cell lung cancer: a restrospective study
Authors: E. Gaudino, G. Borra, S. Genestroni, F. D'Avanzo, E. Rigon, C. Saggia, V. Rossi, E. Bertona, R. Buosi, O. Alabiso
Journal: Annals of Oncology (2015)
AB0626 The Impact of Cyclophosphamide Exposure on Menstrual Cycle in Systemic Lupus Erythematosus Patients
Authors: Z.S. Arici, E.D. Batu, Y. Bilginer, S. Ozen
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is about 10 times more common in females s and during cytotoxic treatment with cyclophosphamide (CYC) is often used for renal involvement. CYC has significant gonadotoxic effects increasing the risk for primary ovarian insufficiency (POI). <h3>Objectives</h3> In this study, we aim to assess symptoms of ovarian failure in females with SLE who underwent CYC therapy and to compare menstrual parameters with SLE patients who did not use CYC previously. <h3>Methods</h3> Eighteen female SLE patients with and without prior CYC exposure were included in the study group. The patients had been followed at the Department of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey. They all received six pulses of IV CYC. The parameters about menstrual cycles and fertility of patients were evaluated retrospectively. SPSS 15.0 for Windows is used for statistical analysis. <h3>Results</h3> We enrolled 18 SLE patients, 10 of whom had received CYC therapy previously. Among females with prior CYC exposure (median current age 21 years), the median age at SLE diagnosis was 11 (10-13) years and the median age at initiation of CYC therapy was 11 (10.5-15) years. All had received CYC intravenously with a median cumulative dose of 94 (62-109) mg/kg. Six out of 10 patients had received CYC before menarche. Only one patient had irregular menses after CYC therapy; she had a cumulative dose of 95 mg/kg and CYC was given to her three years before menarch. In the control group (n=7), the median age at SLE diagnosis was 11.5 (9-17.5) years and median current age was 18.25 (14.5-24) years. One patient in the control group also had irregular menses. The patients were interviewed median 10 years (2-14.5) years later. Two pregnancies were reported, one (live birth) in CYC group and the other one (however resulted in abortus) in the control group. There was no significant difference between two groups according to the current age, age at SLE diagnosis, age at menarche, regularity of menses, and number of pregnancies. <h3>Conclusions</h3> In our study there was no significant difference between two groups of SLE patients (CYC versus CYC-naïve). Previous studies have shown the cumulative dose of CYC and patient age at initiation of CYC therapy determine ovarian toxicity. The young age at onset of CYC therapy in our patients (which is before menarche in six) may be the factor limiting the extent of ovarian damage. <h3>References</h3> Harward LE, Mitchell K, Pieper C, et al. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus 2013;22(1):81-6. Marder W, Fisseha S, Ganser MA, Somers EC. Ovarian Damage During chemotherapy in Autoimmune Diseases: Broad Health Implications beyond Fertility. Clin Med Insights Reprod Health 2012;2012(6):9-18. <h3>Disclosure of Interest</h3> None declared
SP0099 Which Drugs Modify the Course of Axial Spondyloarthritis?
Authors: J. Sieper
Journal: Annals of the Rheumatic Diseases (2015)

Signs and symptoms, function and structural damage are treatment targets to modify the course of disease in axial spondyloarthritis (axSpA). Most data are available on the effect of treatment on signs and symptoms. The best treatment effects can be expected both for treatment with NSAIDs and TNF-blockers if patients are treated early in the course of their disease. TNF-blockers are also more effective in patients who have objective signs of inflammation such as positive CRP and/or active bony inflammation on MRI. Recent data indicate that function improves fast and maintains at a good level if disease activity is treated effectively with TNF-blocker over time, even in the case of progression of structural damage. For an effect of TNF-blockers on structural damage an intervention early in the course of the disease seems to be necessary. NSAIDs might also prevent structural damage in axial SpA, although such an effect was not found in all studies. Whether there is a different effect among NSAIDs on prevention of structural is not clear. Drugs targeting IL-17 or IL-23 have also a good effect on signs and symptoms in ax SpA. Their potential effect on other aspects of disease modification is still under investigation. Currently it is not clear, whether a combination of drugs discussed here might have a superior effect on disease modification than treatment with one drug alone. <h3>Disclosure of Interest</h3> None declared
SAT0032 A Novel Osteogenic Activity Associated with Suberoylanilide Hydroxamic Acid (SAHA) is Synergized With BMP-2
Authors: Z.H. Lee
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> A great deal numbers of histone-deacetylase inhibitors (HDACs) have been well recognized as potential anti-cancer drugs. Inhibition of HDAC induces temporal transcription or epigenetic control, regulating many different biological responses. <h3>Objectives</h3> Due to this notable feature associated with HDACs it occurs to a rational concept that HDAC may be also involved in differentiation osteoblasts (OB). Consistent with this concept we have previously reported that MS-275, a HDAC, affected differentiation of OB via induction of a DNA helicase called Dhs36. Here, we investigated the osteogenic effect of suberoylanilide hydroxamic acid (SAHA). <h3>Methods</h3> The effects of SAHA on osteoblast differentiation were examined in 6XOSE-Luc reporter assay and alkaline phosphatase activity (ALP) assay in activity and immunoprecipitation assay with Runx2. The osteogenic activity of SAHA was determined in vivo in a sRANKL-induced osteoporotic model. <h3>Results</h3> SAHA was able to augment transcriptional activity of Runx2 in a dose-dependent manner shown by a 6XOSE-Luc reporter assay. SAHA by itself was unable to induce ALP, however, SAHA increased ALP activity synergized with BMP-2. The degree of acetylation of Runx2 was increased with the treatment of SAHA, indicating that the transcriptional activity associated with Runx2 might depend on stabilization of an acetylated Runx2. Also, SAHA showed the inhibition of bone loss in sRANL-induced osteoporotic mice model. <h3>Conclusions</h3> Our study shows an intriguing osteogenic potential of SAHA in a BMP-2 dependent manner, suggesting that SAHA could be used at lower doses along with BMP-2 to treat osteoporosis. <h3>References</h3> Kim et al. Histone Deacetylase Inhibitor MS-275 Stimulates Bone Formation in Part by Enhancing Dhx36-Mediated TNAP Transcription. J Bone Miner Res. 2011, 26:2161-2173. <h3>Acknowledgements</h3> This work was supported by a grant of the Korean Health Technology R&amp;D Project, Ministry of Health &amp; Welfare (A120850). <h3>Disclosure of Interest</h3> None declared
Timing of Primary Prophylaxis G-CSF Use during Chemotherapy in Elderly Patients with NHL
Authors: Shuling Li, Iberia Romina Sosa, Julia T Molony, John H Page, Richard L Barron, Jiannong Liu, Phuong Khanh Morrow, Scott Stryker, John F Acquavella, Allan J Collins
Journal: Blood (2014)
PTU-096 Preferences for hepatitis c testing: a discrete choice experiment with methadone users in tayside, scotland
Authors: A Radley, M van der Pol, J Dillon
Journal: Gut (2015)

<h3>Introduction</h3> Currently, only a small number of methadone users are tested for hepatitis C virus (HCV) even though the greatest risk of acquiring the virus is through injecting drug use. To improve the uptake it is crucial to understand patients' preferences for testing so that the service can be redesigned to optimise uptake. Testing can be performed by a number of providers including drug workers and GPs. More recently, Dried Blood Spot testing (DBST) can also be performed within pharmacies. The daily contact with patients, through collection of opioid replacement therapy (ORT), may increase testing rates. However, little is known about whether ORT users would prefer to have their testing at the pharmacy. This study used a survey technique called Discrete Choice Experiments (DCE) to elicit ORT users' preference for HCV testing. DCEs provide information on the relative importance of testing attributes such as type of provider and waiting time. This study also investigated whether the use of incentives may help improve uptake of testing and if so by how much. <h3>Method</h3> Attributes of DBST were identified through the literature and by means of a focus group series with OST users. The attributes were: provider (pharmacy (own and other), drug worker, GP); whether treated with dignity and respect; travel distance; waiting time for results; and incentive payment. Participants were asked to choose between two different tests which varied in terms of the attributes, or a "no test" option. There were 16 choices in total. Conditional logit analysis using STATA was used to estimate the relative importance of each of the attributes. The sample consisted of 77 ORT users in Tayside. <h3>Results</h3> The results showed that ORT users preferred to be tested at their own pharmacy, followed by drug worker, GP and other pharmacy. The most important attribute was whether they were treated with dignity and respect. On average, incentives were not important to ORT users. However, there was heterogeneity within the sample with a sub-group preferring to receive incentives. Very few respondents opted out (chose no test). This is surprising given the current low uptake. This may suggest presence of hypothetical bias (respondents not doing in real life what they say they would do in the DCE) and/or may reflect that they are not routinely offered testing. <h3>Conclusion</h3> To increase uptake testing should be provided within pharmacies whilst ensuring that ORT users are treated with dignity and respect. The use of incentives may improve uptake rates in a sub sample of OST users only. The preference for pharmacy provision of HCV testing may suggest that a full pharmacy pathway, which includes treatment also, has the potential to optimise HCV outcomes. <h3>Disclosure of interest</h3> None Declared.
Evidence for a signaling role for the alpha chains of granulocyte- macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors: divergent signaling pathways between GM-CSF/IL-3 and IL-5
Authors: A Mire-Sluis, LA Page, M Wadhwa, R Thorpe
Journal: Blood (1995)
Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial
Authors: Maria Sessa, Laura Lorioli, Francesca Fumagalli, Serena Acquati, Daniela Redaelli, Cristina Baldoli, Sabrina Canale, Ignazio D Lopez, Francesco Morena, Andrea Calabria, Rossana Fiori, Paolo Silvani, Paola M V Rancoita, Michela Gabaldo, Fabrizio Benedicenti, Gigliola Antonioli, Andrea Assanelli, Maria Pia Cicalese, Ubaldo del Carro, Maria Grazia Natali Sora, Sabata Martino, Angelo Quattrini, Eugenio Montini, Clelia Di Serio, Fabio Ciceri, Maria Grazia Roncarolo, Alessandro Aiuti, Luigi Naldini, Alessandra Biffi
Journal: The Lancet (2016)
Early Intravenous Beta-Blockers in Patients With ST-Segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Intervention
Authors: Vincent Roolvink, Borja Ibáñez, Jan Paul Ottervanger, Gonzalo Pizarro, Niels van Royen, Alonso Mateos, Jan-Henk E. Dambrink, Noemi Escalera, Erik Lipsic, Agustín Albarran, Antonio Fernández-Ortiz, Francisco Fernández-Avilés, Javier Goicolea, Javier Botas, Wouter Remkes, Victoria Hernandez-Jaras, Elvin Kedhi, José L. Zamorano, Felipe Navarro, Fernando Alfonso, Alberto García-Lledó, Joaquin Alonso, Maarten van Leeuwen, Robin Nijveldt, Sonja Postma, Evelien Kolkman, Marcel Gosselink, Bart de Smet, Saman Rasoul, Jan J. Piek, Valentin Fuster, Arnoud W.J. van 't Hof
Journal: Journal of the American College of Cardiology (2016)
Left Main Coronary Artery Atresia in Young Man Examined With 99mTc-Tetrofosmin SPECT
Authors: Lucia Rampin, Massimo Rinuncini, Marco Zuin, GianLuca Rigatelli, Loris Roncon, Patrick M. Colletti, Domenico Rubello
Journal: Clinical Nuclear Medicine (2016)

A young man underwent 99mTc-tetrofosmin cardiac SPECT/CT for the evaluation of the 8-month history of exertional dyspnea without chest pain. 99mTc-tetrofosmin SPECT demonstrated absence of perfusion defects and a mildly decreased uptake in post-stress images, consistent with artifact, in the inferior myocardium. Cardiac catheterization showed a large right and a small left coronary artery opacified retrogradely by right collateral vessels without connections between the left main and the left coronary artery. In patients with anomalous coronary arteries, 99mTc SPECT can shows absence of perfusion defects, in the presence of a collateral circulation.
CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Authors: Ele Ferrannini, Michael Mark, Eric Mayoux
Journal: Diabetes Care (2016)

The striking and unexpected relative risk reductions in cardiovascular (CV) mortality (38%), hospitalization for heart failure (35%), and death from any cause (32%) observed in the EMPA-REG OUTCOME trial using an inhibitor of sodium-glucose cotransporter 2 (SGLT2) in patients with type 2 diabetes and high CV risk have raised the possibility that mechanisms other than those observed in the trial-modest improvement in glycemic control, small decrease in body weight, and persistent reductions in blood pressure and uric acid level-may be at play. We hypothesize that under conditions of mild, persistent hyperketonemia, such as those that prevail during treatment with SGLT2 inhibitors, β-hydroxybutyrate is freely taken up by the heart (among other organs) and oxidized in preference to fatty acids. This fuel selection improves the transduction of oxygen consumption into work efficiency at the mitochondrial level. In addition, the hemoconcentration that typically follows SGLT2 inhibition enhances oxygen release to the tissues, thereby establishing a powerful synergy with the metabolic substrate shift. These mechanisms would cooperate with other SGLT2 inhibition-induced changes (chiefly, enhanced diuresis and reduced blood pressure) to achieve the degree of cardioprotection revealed in the EMPA-REG OUTCOME trial. This hypothesis opens up new lines of investigation into the pathogenesis and treatment of diabetic and nondiabetic heart disease.
Double-balloon enteroscopy-assisted endoscopic retrograde cholangiography for the treatment of a strictured Roux-en-Y hepaticojejunal anastomosis
Authors: Gabriela Paduani, Adriana Saflatle-Ribeiro, Matheus Franco, Fauze Maluf-Filho
Journal: Endoscopy (2015)

A 49-year-old patient underwent cholecystectomy and Roux-en-Y hepaticojejunal anastomosis ([Fig. 1]) for Mirizzi's syndrome. Jaundice, pruritus, choluria, and acholia developed 4 months later. The total serum bilirubin was 21 mg/dL, and magnetic resonance cholangiopancreatography (MRCP) demonstrated intrahepatic bile duct dilation and anastomotic stricture.
Is everyone depressed?
Authors: R A Woodruff, P J Clayton, S B Guze
Journal: American Journal of Psychiatry (1975)

The authors collected a large number of research interviews with relatives of patients from a psychiatric research clinic. Half of these patients were clinically depressed; their relatives as well as the rest of the relatives interviewed were therefore at high risk for depression. However, few of the relatives reported memorable dysphoria or any clustered episodes of other affective symptoms. The authors conclude from these data that, contrary to the opinions expressed by some, not everyone has episodes of depression. Everybody is not depressed.